Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuo TherapeuticsAURX +4.83%24 3-Year EBITDA Growth Rate is 13.40% as of Jun. 2026, which is 37% above its 10-year median of 9.80. GuruFocus rates AURX with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 1,122 Biotechnology companies, Nuo Therapeutics ranks worse than 51.87% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -102.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nuo Therapeutics was 87.20% per year. The lowest was -231.70% per year. And the median was 9.80% per year.
Nuo Therapeutics (OTCPK:AURX) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nuo Therapeutics 3-Year EBITDA Growth Rate Related Terms
AURX vs TIL, ATYR, NTRB: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Nuo Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's 3-Year EBITDA Growth Rate falls into.
Nuo Therapeutics 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.40% mean?
Nuo Therapeutics (AURX) has a 3-Year EBITDA Growth Rate of 13.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nuo Therapeutics and its competitors. This is 37% above median its historical median of 9.80. According to the industry distribution chart, Nuo Therapeutics ranks #582 out of 1122 companies in the Biotechnology industry, placing it in the top 51.9%.
Is Nuo Therapeutics' 3-Year EBITDA Growth Rate too high?
Nuo Therapeutics' current 3-Year EBITDA Growth Rate of 13.40% is 37% above median its 10-year median of 9.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.75. Nuo Therapeutics' value of 13.40% is 9.2% below this industry median. Based on the distribution chart, Nuo Therapeutics ranks #582 out of 1122 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nuo Therapeutics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' 3-Year EBITDA Growth Rate compare to TIL and ATYR?
According to the Biotechnology industry distribution chart, Nuo Therapeutics ranks #582 out of 1122 companies for 3-Year EBITDA Growth Rate. This places Nuo Therapeutics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.75. Nuo Therapeutics' value of 13.40% is 9.2% below this benchmark. While the company's 10-year median is 9.80 vs. the industry median of 14.75, Nuo Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.75, based on 1,122 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuo Therapeutics's current 3-Year EBITDA Growth Rate of 13.40% is 9.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nuo Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuo Therapeutics's current 3-Year EBITDA Growth Rate is 13.40%, which is 37% above median its own 10-year median of 9.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Nuo Therapeutics (AURX) has a current 3-Year EBITDA Growth Rate of 13.40%. The current 3-Year EBITDA Growth Rate is 13.40%, which is 37% above median its 10-year median of 9.80 and 9.2% below the Biotechnology industry median of 14.75. Nuo Therapeutics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current 3-Year EBITDA Growth Rate is 13.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
24GF Score
Get the complete analysis for AURX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 
